- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Obstetrics and Gynecology International
Volume 2013 (2013), Article ID 828165, 10 pages
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
1Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
2Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
3Gillette Center for Gynecological Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Received 31 May 2013; Accepted 10 October 2013
Academic Editor: Andrew P. Bradford
Copyright © 2013 Xiangbing Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- “Cancer facts and figures,” 2011, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
- C. Aghajanian, M. W. Sill, K. M. Darcy et al., “Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2259–2265, 2011.
- F. Heitz, P. Harter, J. Barinoff et al., “Bevacizumab in the treatment of ovarian cancer,” Advances in Therapy, vol. 29, no. 9, pp. 723–735, 2012.
- B. J. Monk, H. Dalton, J. H. Farley, D. M. Chase, and I. Benjamin, “Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer,” Critical Reviews in Oncology / Hematology, vol. 86, no. 2, pp. 161–175, 2013.
- E. S. Santos, J. E. Gomez, and L. E. Raez, “Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor,” Investigational New Drugs, vol. 30, no. 3, pp. 1261–1269, 2011.
- K. J. Dedes, D. Wetterskog, A. Ashworth, S. B. Kaye, and J. S. Reis-Filho, “Emerging therapeutic targets in endometrial cancer,” Nature Reviews Clinical Oncology, vol. 8, no. 5, pp. 261–271, 2011.
- M. Llaurado, A. Ruiz, B. Majem et al., “Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease,” Molecular and Cellular Endocrinology, vol. 358, no. 2, pp. 244–255, 2011.
- H. Liang, L. W. Cheung, J. Li et al., “Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer,” Genome Research, vol. 22, no. 11, pp. 2120–2129, 2012.
- C. Kandoth, N. Schultz, A. D. Cherniack et al., “Integrated genomic characterization of endometrial carcinoma,” Nature, vol. 497, no. 7447, pp. 67–73, 2013.
- T. Aas, A.-L. Borresen, S. Geisler et al., “Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients,” Nature Medicine, vol. 2, no. 7, pp. 811–814, 1996.
- G. Blandino, A. J. Levine, and M. Oren, “Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy,” Oncogene, vol. 18, no. 2, pp. 477–485, 1999.
- W.-P. Tsang, F. Y. F. Ho, K.-P. Fung, S.-K. Kong, and T.-T. Kwok, “P53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis,” International Journal of Cancer, vol. 114, no. 3, pp. 331–336, 2005.
- J. Bartek and J. Lukas, “Chk1 and Chk2 kinases in checkpoint control and cancer,” Cancer Cell, vol. 3, no. 5, pp. 421–429, 2003.
- M. B. Kastan and J. Bartek, “Cell-cycle checkpoints and cancer,” Nature, vol. 432, no. 7015, pp. 316–323, 2004.
- H. C. Reinhardt, P. Hasskamp, I. Schmedding et al., “DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization,” Molecular Cell, vol. 40, no. 1, pp. 34–49, 2010.
- T. O'Neill, L. Giarratani, P. Chen et al., “Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 16102–16115, 2002.
- I. A. Manke, A. Nguyen, D. Lim, M. Q. Stewart, A. E. H. Elia, and M. B. Yaffe, “MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G 2/M transition and S phase progression in response to UV irradiation,” Molecular Cell, vol. 17, no. 1, pp. 37–48, 2005.
- R. Boutros, V. Lobjois, and B. Ducommun, “CDC25 phosphatases in cancer cells: key players? good targets?” Nature Reviews Cancer, vol. 7, no. 7, pp. 495–507, 2007.
- A. Gurtner, G. Starace, G. Norelli, G. Piaggio, A. Sacchi, and G. Bossi, “Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function,” Journal of Biological Chemistry, vol. 285, no. 19, pp. 14160–14169, 2010.
- A. Behren, S. Muhlen, G. A. Acuna Sanhueza et al., “Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion,” Oncogene, vol. 29, no. 10, pp. 1519–1530, 2010.
- K. Strebhardt, “Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy,” Nature Reviews Drug Discovery, vol. 9, no. 8, pp. 643–660, 2010.
- V. A. J. Smits, R. Klompmaker, L. Arnaud, G. Rijksen, E. A. Nigg, and R. H. Medema, “Polo-like kinase-1 is a target of the DNA damage checkpoint,” Nature Cell Biology, vol. 2, no. 9, pp. 672–676, 2000.
- P. S. Kho, Z. Wang, L. Zhuang et al., “P53-regulated transcriptional program associated with genotoxic stress-induced apoptosis,” Journal of Biological Chemistry, vol. 279, no. 20, pp. 21183–21192, 2004.
- M. A. T. M. Van Vugt and R. H. Medema, “Getting in and out of mitosis with polo-like kinase-1,” Oncogene, vol. 24, no. 17, pp. 2844–2859, 2005.
- S. Sur, R. Pagliarini, F. Bunz et al., “A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3964–3969, 2009.
- L. McKenzie, S. King, L. Marcar et al., “P53-dependent repression of polo-like kinase-1 (PLK1),” Cell Cycle, vol. 9, no. 20, pp. 4200–4212, 2010.
- J. Tang, X. Yang, and X. Liu, “Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression,” Oncogene, vol. 27, no. 52, pp. 6635–6645, 2008.
- X. Meng, L. L. Laidler, E. A. Kosmacek et al., “Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53,” Gynecologic Oncology, vol. 128, no. 3, pp. 461–469, 2013.
- M. V. Blagosklonny, J. Toretsky, S. Bohen, and L. Neckers, “Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8379–8383, 1996.
- R. Brosh and V. Rotter, “When mutants gain new powers: news from the mutant p53 field,” Nature Reviews Cancer, vol. 9, no. 10, pp. 701–713, 2009.
- D. Li, N. D. Marchenko, and U. M. Moll, “SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis,” Cell Death and Differentiation, vol. 18, no. 12, pp. 1904–1913, 2011.
- P. Brachova, K. W. Thiel, and K. K. Leslie, “The consequence of oncomorphic TP53 mutations in ovarian cancer,” International Journal of Molecular Sciences, vol. 14, no. 9, pp. 19257–19275, 2013.
- M. Wiech, M. B. Olszewski, Z. Tracz-Gaszewska, B. Wawrzynow, M. Zylicz, and A. Zylicz, “Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2,” PLoS One, vol. 7, no. 12, Article ID e51426, 2012.
- D. P. Liu, H. Song, and Y. Xu, “A common gain of function of p53 cancer mutants in inducing genetic instability,” Oncogene, vol. 29, no. 7, pp. 949–956, 2010.
- L. H. Hartwell, P. Szankasi, C. J. Roberts, A. W. Murray, and S. H. Friend, “Integrating genetic approaches into the discovery of anticancer drugs,” Science, vol. 278, no. 5340, pp. 1064–1068, 1997.